Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcγRI and the epidermal growth factor receptor

Cancer Immunology Immunotherapy

Volumn 49, Issue 9, 2000, Pages 493-503

  Wallace, Paul K ^a   Romet Lemonne, Jean Loup ^b   Chokri, Mohammed ^b   Kasper, Lloyd H ^a   Fanger, Michael W ^a   Fadul, Camilo E ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Immuno Designed Molecules   (France)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Bispecific antibody; EGFR; Fc receptor; Glioblastoma multiforme; MAK cell; Phagocytosis

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN G;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; EFFECTOR CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKAPHERESIS; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0033766761     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000142     Document Type: Article

References (63)

1. Molecular basis of macrophage activation diversity and its origin
2. Phagocytosis mediated by three distinct Fcγ receptor classes on human leukocytes
3. Adoptive immunotherapy of cancer using monocyte-derived macrophages: Rationale, current status, and perspectives
4. Altered monocyte chemotactic and activating factor gene expression in human glioblastoma cell lines increased their susceptibility to cytotoxicity
5. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells
6. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture
7. Generation of phagocytic MAK and MAC-DC for therapeutic use: Characterization and in vitro functional properties
8. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis
9. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: Application in bone marrow transplantation
10. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3
11. Epidermal growth factor gene and its transcripts in glioblastomas
12. Clinical experience with CD64-directed immunotherapy
13. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene
14. Bispecific monoclonal antibody anti-CD3 x anti-tenascin: An immunotherapeutic agent for human glioma
15. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor
16. Long term cultures of human monocytes in vitro. Impact of GM-CSF on survival and differentiation
17. Bispecific-armed, IFNγ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma
18. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
19. Cytotoxicity mediated by human Fc receptors for IgG
20. Type I (CD64) and type II (CD32) Fcg receptor-mediated phagocytosis by human blood dendritic cells
21. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor FcγRI (CD64) expressed on human blood dendritic cells
22. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions
23. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
24. Human neutrophil Fc gamma receptor distribution and structure
25. Glioblastoma-associated circulating monocytes and the release of epidermal growth factor
26. Preparation and performance of bispecific F(ab'γ)2 antibody containing thioether-linked Fab'γ fragments
27. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes
28. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function
29. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells
30. Prolongation of allograft survival by 1,25-dihydroxyvitamin D3
31. Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway
32. MC 1288-a vitamin D analogue with immunosuppressive effects on heart and small bowel grafts
33. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells
34. Activated monocytes kill malignant brain tumor cells in vitro
35. Induction of human monocyte to macrophage maturation in vitro by 1,25-dihydroxyvitamin D3
36. Human monocytes and U937 cells bear two distinct Fc receptors for IgG
37. The origin and function of tumor-associated macrophages
38. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations
39. Macrophage heterogeneity
40. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level
41. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages
42. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody
43. Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells
44. Preliminary trial of specific targeting therapy against malignant glioma
45. The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs
46. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T Cell activation
47. Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells
48. Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-γ and glucocorticoids
49. Macrophages in tumour immunity
50. Fcγ Receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I restricted antigen presentation after immune complex internalization
51. Neutrophils express the high affinity receptor for IgG (FcγRI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
52. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes
53. Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate
54. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity
55. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate
56. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas
57. Role of Fcγ receptors in cancer and infectious disease
58. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcγRI), blocks phagocytosis and modulates receptor expression
59. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain
60. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma
61. Epidermal growth factor receptor expression in human malignant glioma: In vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor
62. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers